Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

Tadashi Matsushita, Pratima Chowdary, Atanas Mitkov Banchev, Kaan Kavakli, Johanna A. Kremer Hovinga, Jerzy Windyga, Víctor Jiménez-Yuste, Julien Bovet, Llenalia María García Fernández, Guy Young

Blood (2024) 144 (Supplement 1): 718.

https://doi.org/10.1182/blood-2024-198617

Published: 2024

Journal Articles

FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A

Guy Young, Katherine Eakle, Elise Lim, Michael Wang

Blood (2024) 144 (Supplement 1): 2589.

https://doi.org/10.1182/blood-2024-193816

Published: 2024

Journal Articles

Assessment of the Combined Effects of Emicizumab and Fitusiran with in Vitro Spiking of Simulated Fitusiran (using anti-thrombin antibody) into Plasma from Hemophilia a Patients on Emicizumab

Sibgha Zaheer, Elizabeth Marquez Casas, Myew-Ling Toh, Guy Young

Blood (2024) 144 (Supplement 1): 132.

https://doi.org/10.1182/blood-2024-206336

Published: 2024

Journal Articles

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Blood (2024) 143 (22): 2256–2269.

https://doi.org/10.1182/blood.2023021864

Published: 2024

Includes: Supplemental data

Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2024) 143 (14): 1355–1364.

https://doi.org/10.1182/blood.2023021832

Published: 2024

Includes: Supplemental data

Journal Articles

How I treat pediatric venous thromboembolism in the DOAC era

Rukhmi V. Bhat, Guy Young, Anjali A. Sharathkumar

Blood (2024) 143 (5): 389–403.

https://doi.org/10.1182/blood.2022018966

Published: 2024

Journal Articles

Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B

Blood (2023) 142 (Supplement 1): 1055.

https://doi.org/10.1182/blood-2023-187624

Published: 2023

Journal Articles

Inflammation Sub-Group Analysis in Pediatric HA-VTE Cases: A Report from the Children's Hospital Acquired Thrombosis Registry (CHAT) Registry

Taylor Harp, Kailey Proctor, Maua Mosha, Allaura Cox, Julie Jaffray, Amy Stillings, Emily Krava, Ernest K Amankwah, E. Vincent Faustino, Neil A. Zakai, Guy Young, Neil Goldenberg, Brian R. Branchford

Blood (2023) 142 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2023-190491

Published: 2023

Journal Articles

Identifying Ideal Individuals for PK-Guided Dosing; Recreational Risks and Elevated Breakthrough Bleeding

Guy Young, Vinod V. Balasa, Jonathan C. Roberts, Andrew Frick, Ali G Mokdad, Jorge Caicedo

Blood (2023) 142 (Supplement 1): 3742.

https://doi.org/10.1182/blood-2023-178042

Published: 2023

Journal Articles

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Steven Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Markus Niggli, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 505.

https://doi.org/10.1182/blood-2023-177963

Published: 2023

Journal Articles

Multicenter Study of a Risk Prediction Model for Critically Ill Children at High-Risk for Hospital-Acquired Venous Thromboembolism: Findings from the Children's Hospital-Acquired Thrombosis (CHAT) Consortium

Julie Jaffray, Maua Mosha, Brian R. Branchford, Ernest K Amankwah, E. Vincent Faustino, Emily Krava, Amy Stillings, Guy Young, Neil Goldenberg

Blood (2023) 142 (Supplement 1): 809.

https://doi.org/10.1182/blood-2023-187395

Published: 2023

Journal Articles

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Robert Klamroth, Robert F Sidonio, Jr., Yesim Dargaud, Víctor Jiménez-Yuste, Rolf Ljung, Guy Young, Pratima Chowdary

Blood (2023) 142 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2023-181725

Published: 2023

Journal Articles

The Effect of Concizumab Prophylaxis on Target Joints, Resolution and Joint Bleeds in Patients With Hemophilia A or B With or Without Inhibitors in Phase 3 Clinical Trials

Giancarlo Castaman, Aby Abraham, Pantep Angchaisuksiri, Laura Villarreal Martinez, Keiji Nogami, Jameela Sathar, Chunduo Shen, Jay Jay Thaung Zaw, Guy Young

Blood (2023) 142 (Supplement 1): 284.

https://doi.org/10.1182/blood-2023-180790

Published: 2023

Journal Articles

Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study

Gili Kenet, Beatrice Nolan, Tadashi Matsushita, Guy Young, Ting Quan, Viridiana Cano, Christian Sussebach, Shauna Andersson, Baisong Mei, Marion Afonso, Kaan Kavakli

Blood (2022) 140 (Supplement 1): 7977–7978.

https://doi.org/10.1182/blood-2022-167169

Published: 2022

Journal Articles

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2022) 140 (Supplement 1): 457–459.

https://doi.org/10.1182/blood-2022-157264

Published: 2022

Journal Articles

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Amy L. Dunn, Yesim Dargaud, Yasmina L. Abajas, Manuel Carcao, Giancarlo Castaman, Adam Giermasz, Cédric Hermans, Magdalena D. Lewandowska, Johnny Mahlangu, Shannon L. Meeks, Wolfgang A. Miesbach, Michael Recht, Vanessa Salinas, Tammuella Chrisentery-Singleton, Hongying Wang, Ian S Mitchell, Guy Young

Blood (2022) 140 (Supplement 1): 8485–8488.

https://doi.org/10.1182/blood-2022-157343

Published: 2022

Journal Articles

Discrepancy between the Results of One-Stage and Chromogenic Factor VIII Assays: Switch in Diagnosis from Mild to Moderate Hemophilia a in Three Cases

Hande Kizilocak, Jackie Keegan, Guy Young

Blood (2022) 140 (Supplement 1): 11310–11311.

https://doi.org/10.1182/blood-2022-168423

Published: 2022

Journal Articles

The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results

Gili Kenet, Ampaiwan Chuansumrit, Tadashi Matsushita, Guy Young, Vandana Yadav, Marek Zak, Christoph Male

Blood (2022) 140 (Supplement 1): 2726–2727.

https://doi.org/10.1182/blood-2022-162331

Published: 2022

Journal Articles

Can we do something about ICH in hemophilia?

Guy Young

Blood (2021) 138 (26): 2750–2751.

https://doi.org/10.1182/blood.2021013536

Published: 2021

Journal Articles

PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol

Guy Young, Mark T Reding, Robert F. Sidonio, Jr., Doris V. Quon, Janice M. Staber, Cindy A. Leissinger, Jessica Charlet, Moncef Boukerrou

Blood (2021) 138 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2021-148700

Published: 2021

NARROW

Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A

Assessment of the Combined Effects of Emicizumab and Fitusiran with in Vitro Spiking of Simulated Fitusiran (using anti-thrombin antibody) into Plasma from Hemophilia a Patients on Emicizumab

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

How I treat pediatric venous thromboembolism in the DOAC era

Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B

Inflammation Sub-Group Analysis in Pediatric HA-VTE Cases: A Report from the Children's Hospital Acquired Thrombosis Registry (CHAT) Registry

Identifying Ideal Individuals for PK-Guided Dosing; Recreational Risks and Elevated Breakthrough Bleeding

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Multicenter Study of a Risk Prediction Model for Critically Ill Children at High-Risk for Hospital-Acquired Venous Thromboembolism: Findings from the Children's Hospital-Acquired Thrombosis (CHAT) Consortium

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

The Effect of Concizumab Prophylaxis on Target Joints, Resolution and Joint Bleeds in Patients With Hemophilia A or B With or Without Inhibitors in Phase 3 Clinical Trials

Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Discrepancy between the Results of One-Stage and Chromogenic Factor VIII Assays: Switch in Diagnosis from Mild to Moderate Hemophilia a in Three Cases

The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results

Can we do something about ICH in hemophilia?

PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only